{"id":"W2956888684","doi":"10.1016/s2352-3026(19)30109-7","title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Merck Sharp and Dohme","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Interim analysis; Pembrolizumab; Adverse effect; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003482482,0.0003845846,0.002038338,0.0001112085,0.0002188243,0.00007307438,0.0003230142,0.000148658,0.0001229703],"category_scores_gemma":[0.0005575231,0.0002056558,0.00009418201,0.0001465512,0.0002564505,0.0001453894,0.0001482918,0.0001887996,0.00008381254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001671936,"about_ca_system_score_gemma":0.000272907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002370549,"about_ca_topic_score_gemma":0.0001118411,"domain_scores_codex":[0.9975913,0.0003133435,0.0004062384,0.0006032133,0.0002825943,0.0008033238],"domain_scores_gemma":[0.9966329,0.001913061,0.0002339933,0.0007801412,0.0001774475,0.0002624742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9577143,0.002240359,0.02791091,0.0001752006,0.0009861686,0.0001789347,0.0003965448,0.000001746144,0.0001985604,0.000291321,0.000601546,0.009304404],"study_design_scores_gemma":[0.9773819,0.01416254,0.002761687,0.0000934118,0.0004598101,0.0002759568,0.0000780772,0.001570536,0.0007777246,0.0001617074,0.00204817,0.0002285021],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827675,0.0003726385,0.0001812847,0.001316658,0.0001624709,0.01432163,0.0002068293,0.00005855868,0.0006124033],"genre_scores_gemma":[0.9934601,0.000136929,0.002719304,0.0003190514,0.000187568,0.001909133,0.000325384,0.00005967223,0.0008829238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02514923,"threshold_uncertainty_score":0.8386402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07617864432414798,"score_gpt":0.3729354676185405,"score_spread":0.2967568232943925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}